Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s disease

Abstract Background: Levodopa is the mainstay of Parkinson’s disease (PD) treatment, but is often eventually associated with disabling motor complications in patients with advanced PD. The inability of perorally administered levodopa to provide more physiologic continuous dopaminergic stimulation (CDS) is a leading hypothesis to explain these complications. Objective: To investigate the cumulative efficacy and safety, and re-evaluate the role, of levodopa–carbidopa intestinal gel (LCIG) infusion in treatment of advanced PD patients experiencing levodopa-associated motor complications, through its purported mechanism for providing CDS. Methods: Literature searches in the MEDLINE/PubMed database were used to identify peer-reviewed publications examining the role of CDS in levodopa-associated motor complications and pharmacologic strategies for CDS, focusing on LCIG infusion for advanced PD patients. Results: LCIG, an aqueous gel, is continuously infused (daytime only or 24 h) via a portable pump and tube permanently inserted into the duodenum through percutaneous endoscopic gastrostomy (PEG). LCIG infusion provides stable levodopa plasma levels, which are significantly less variable than those with oral levodopa. Clinical trials indicate LCIG may significantly improve motor complications (reduction of time in ‘off’ and time in ‘on with dyskinesias’), motor scores using the Unified Parkinson’s Disease Rating Scale (UPDRS), non-motor symptomatology (Non-motor Symptom Scale) and health-related quality of life (HRQOL) in advanced PD patients. The adverse-event profile of LCIG is similar to that of oral levodopa, although technical problems with the infusion device have occurred in up to 70% of patients. Conclusion: LCIG has demonstrated efficacy in reducing levodopa-associated motor complications in patients with advanced PD, and improving UPDRS and HRQOL scores. Because it involves PEG and its associated risks, LCIG is recommended for patients in whom motor fluctuations and dyskinesias are inadequately treated with traditional peroral medication. For these patients, LCIG can be a valuable alternative to deep brain stimulation (DBS), especially when DBS is contraindicated. These conclusions are limited by the modest number and size of completed randomized, controlled trials of LCIG.

[1]  J. Dartigues,et al.  A 15-year population-based cohort study of the incidence of Parkinson's disease and dementia with Lewy bodies in an elderly French cohort , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[2]  K. Lyons,et al.  Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[3]  L. Lopiano,et al.  Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome , 2007, Movement disorders : official journal of the Movement Disorder Society.

[4]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. , 2000, JAMA.

[5]  J. Molinuevo,et al.  History of levodopa and dopamine agonists in Parkinson's disease treatment , 1998, Neurology.

[6]  K. Leenders,et al.  Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[7]  T. Lewander,et al.  Enteral Levodopa/Carbidopa Infusion in Advanced Parkinson Disease: Long-term Exposure , 2008, Clinical neuropharmacology.

[8]  W. Birkmayer,et al.  [Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes)]. , 1967, Archiv fur Psychiatrie und Nervenkrankheiten.

[9]  J. Langston,et al.  Double‐blind, placebo‐controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on‐off' fluctuations , 1993, Neurology.

[10]  C. Clarke,et al.  Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. , 2009, Parkinsonism & related disorders.

[11]  O. Rascol,et al.  Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study , 1998, Movement disorders : official journal of the Movement Disorder Society.

[12]  Angelo Antonini,et al.  The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[13]  M. Hallett,et al.  Levodopa in the treatment of Parkinson's disease: Current controversies , 2004, Movement disorders : official journal of the Movement Disorder Society.

[14]  L. Regeur,et al.  [Duodopa pump treatment in patients with advanced Parkinson's disease]. , 2010, Ugeskrift for laeger.

[15]  O. Suchowersky,et al.  Neuropathy as a potential complication of levodopa use in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[16]  J. Potack,et al.  Complications of and controversies associated with percutaneous endoscopic gastrostomy: report of a case and literature review. , 2008, Medscape journal of medicine.

[17]  G. Deuschl,et al.  Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6‐month randomized placebo‐controlled double‐blind study in Germany and Austria (Celomen study) , 2002, Acta neurologica Scandinavica.

[18]  T. Simuni,et al.  Nonmotor manifestations of Parkinson's disease , 2008, Annals of neurology.

[19]  A. Lipp,et al.  Systemic antimicrobial prophylaxis for percutaneous endoscopic gastrostomy. , 2006, The Cochrane database of systematic reviews.

[20]  D. Maraganore,et al.  Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990 , 1999, Neurology.

[21]  A. Antonini,et al.  Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease. , 2009, Parkinsonism & related disorders.

[22]  R. Hauser,et al.  Duodenal levodopa infusion for the treatment of Parkinson’s disease , 2007, Expert opinion on pharmacotherapy.

[23]  Angelo Antonini,et al.  Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management , 2009, Expert review of neurotherapeutics.

[24]  D. Brooks,et al.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.

[25]  L. Schuh,et al.  Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease. , 1988, Clinical neuropharmacology.

[26]  I. Forgacs,et al.  Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life , 2009, Movement disorders : official journal of the Movement Disorder Society.

[27]  C. Lundqvist.  Continuous levodopa for advanced Parkinson’s disease , 2007, Neuropsychiatric disease and treatment.

[28]  S. Aquilonius,et al.  Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease , 2004, European Journal of Clinical Pharmacology.

[29]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[30]  L. Defebvre,et al.  [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety]. , 2009, Revue neurologique.

[31]  J. Leysen,et al.  Apomorphine: chemistry, pharmacology, biochemistry. , 1976, International review of neurobiology.

[32]  D. Nyholm,et al.  Duodenal levodopa infusion in Parkinson's disease – long‐term experience , 2001, Acta neurologica Scandinavica.

[33]  F. Stocchi.  The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease. , 2009, Parkinsonism & related disorders.

[34]  O. Rascol,et al.  Rotigotine transdermal delivery for the treatment of Parkinson's disease. , 2009, Expert opinion on pharmacotherapy.

[35]  W. Birkmayer,et al.  Weitere experimentelle Untersuchungen über den Catecholaminstoffwechsel bei extrapyramidalen Erkrankungen (Parkinson- und Chorea-Syndrom) , 1967, Archiv für Psychiatrie und Nervenkrankheiten.

[36]  H. Lennernäs,et al.  Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release Tablets , 2003, Clinical neuropharmacology.

[37]  D. Nyholm,et al.  Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease , 2005, Neurology.

[38]  S. Stawicki,et al.  Complications related to percutaneous endoscopic gastrostomy (PEG) tubes. A comprehensive clinical review. , 2007, Journal of gastrointestinal and liver diseases : JGLD.

[39]  P. Sonsalla,et al.  Experience with continuous enteral levodopa infusions in the treatment of 9 patients with advanced Parkinson's disease. , 1989, Neurology.

[40]  D. Nyholm,et al.  Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom fluctuations , 2009, Acta neurologica Scandinavica.

[41]  P. LeWitt.  Subcutaneously administered apomorphine: Pharmacokinetics and metabolism , 2004 .

[42]  W. Burkard,et al.  Increase of Cerebral Catecholamines caused by 3,4-Dihydroxyphenylalanine after Inhibition of Peripheral Decarboxylase , 1967, Nature.

[43]  G. Block,et al.  Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. , 1997, European neurology.

[44]  C. Pont‐Sunyer,et al.  Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life. , 2010, Parkinsonism & related disorders.

[45]  Robert A. Hauser,et al.  Levodopa: Past, Present, and Future , 2008, European Neurology.

[46]  D. Devos.  Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[47]  A. Lees,et al.  On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. , 1984, Brain : a journal of neurology.

[48]  M. Juncadella,et al.  Cognitive improvement after duodenal levodopa infusion in cognitively impaired Parkinson's disease patients , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[49]  O Rascol.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group , 2000 .

[50]  J. Nutt,et al.  Erratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobility , 1988, Neurology.

[51]  D. Nyholm,et al.  Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion , 2008, Acta neurologica Scandinavica.

[52]  L. Defebvre,et al.  Intérêts de la stimulation dopaminergique continue par Duodopa ® dans la maladie de Parkinson évoluée : efficacité et tolérance , 2009 .

[53]  Laura B Zahodne,et al.  Parkinson’s Psychosis , 2010, Current treatment options in neurology.

[54]  D. Nyholm.  The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease. , 2007, Parkinsonism & related disorders.

[55]  G. Bono,et al.  Long-term experience with continuous duodenal levodopa–carbidopa infusion (Duodopa): report of six patients , 2009, Neurological Sciences.

[56]  A. Barbeau.  L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. , 1969, Canadian Medical Association journal.

[57]  J. Dartigues,et al.  Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[58]  M. Nirenberg,et al.  Dopamine agonist withdrawal syndrome in Parkinson disease. , 2010, Archives of neurology.

[59]  T. Chase.  The Significance of Continuous Dopaminergic Stimulation in the Treatment of Parkinson’s Disease , 2012, Drugs.

[60]  M. Canesi,et al.  Duodenal Levodopa Infusion Improves Quality of Life in Advanced Parkinson’s Disease , 2008, Neurodegenerative Diseases.

[61]  W R Woodward,et al.  The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. , 1984, The New England journal of medicine.

[62]  Fabrizio Stocchi,et al.  Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications , 2006, The Lancet Neurology.

[63]  M. Mcdermott,et al.  Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. , 2006, Archives of neurology.

[64]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. , 2004, Archives of neurology.

[65]  C. Warren Olanow,et al.  The scientific and clinical basis for the treatment of Parkinson disease (2009) , 2009, Neurology.

[66]  G. Logroscino,et al.  Incidence and remaining lifetime risk of Parkinson disease in advanced age , 2009, Neurology.

[67]  J. Jankovic,et al.  Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study , 2010, Annals of neurology.

[68]  O. Rascol,et al.  Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa , 2006, Movement disorders : official journal of the Movement Disorder Society.

[69]  R. Duvoisin,et al.  Long‐term duodenal infusion of levodopa for motor fluctuations in parkinsonism , 1988, Annals of neurology.

[70]  E. Katunina,et al.  [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[71]  S. Galandiuk,et al.  Meta‐analysis: antibiotic prophylaxis to prevent peristomal infection following percutaneous endoscopic gastrostomy , 2007, Alimentary pharmacology & therapeutics.

[72]  L. Hansson,et al.  Long‐term intraduodenal infusion of a water based levodopa‐carbidopa dispersion in very advanced Parkinson's disease , 1998, Acta neurologica Scandinavica.

[73]  D. Nyholm.  Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson’s disease , 2006, Expert review of neurotherapeutics.

[74]  J. Nutt.  Long-term 24-hour duodenal infusion of levodopa: Outcome and dose requirements , 2006, Neurology.

[75]  Fabrizio Stocchi,et al.  Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. , 2005, Archives of neurology.

[76]  D. Thurman,et al.  How common are the “common” neurologic disorders? , 2007, Neurology.

[77]  F. Horak,et al.  Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. , 2011, Archives of neurology.

[78]  Werner Poewe,et al.  Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa , 2007, Movement disorders : official journal of the Movement Disorder Society.

[79]  W. Oertel,et al.  Continuous Jejunal Levodopa Infusion in Patients With Advanced Parkinson Disease: Practical Aspects and Outcome of Motor and Non-motor Complications , 2008, Clinical neuropharmacology.

[80]  R. Tissot,et al.  Drug-induced changes of extracerebral dopa metabolism in man. , 1969, Archives of neurology.